Efficacy of Lymphatic-Venous Anastomosis Plus Donepezil Versus Donepezil Alone for Alzheimer's Disease

Inclusion Criteria

1. The patient or guardian signs the informed consent form;
2. Age 50-80 years (≥50 years, ≤80 years), male or female;
3. The first diagnosis is Alzheimer's disease with dementia;
4. MMSE score ≤24;
5. Positive β-amyloid protein PET imaging findings;
6. HAMD score ≤17;
7. Hachinski score ≤7;
8. No AD-related drug treatment has been received within the past 1 month;
9. ASA grade 1-3 (≥ grade 1, ≤ grade 3).
10. CDR-SB score of 9.5-15.5

Exclusion Criteria

1. Presence of contraindications to MRI, ICG angiography, or PET scan;
2. Presence of contraindications to lumbar puncture;
3. Severe heart disease or unstable hemodynamic status;
4. Severe lung disease, including severe obstructive, restrictive, or mixed ventilatory dysfunction, or acute inflammation within 3 months;
5. Hepatic insufficiency, AST or ALT >3 times the upper limit of normal;
6. Renal insufficiency, GFR <60 mL/min or need for blood purification treatment;
7. MRI indicates active or acute intracranial lesions, including intracranial infection, space-occupying lesions, major hemorrhage, and ≥4 lobar microbleeds, etc.;
8. History of cerebral hemorrhage or cerebral infarction with severe residual neurological dysfunction;
9. Blood diseases, bleeding/coagulation disorders, coagulation dysfunction;
10. Abnormal thyroid function;
11. Moderate or severe stenosis of intracranial or cervical vessels with severe residual neurological dysfunction;
12. Severe hypertension not effectively controlled, systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg;
13. The disease requires systemic use of steroids;
14. Drug addiction (including alcohol, narcotics, and alcohol dependence);
15. Severe infectious diseases, including HIV positivity, severe infection, etc.;
16. Severe psychiatric disease or potential suicide risk;
17. Within 3 years after radical surgery for malignant tumor;
18. Participation in other interventional clinical trials within the past three months;
19. In the physician's judgment, poor compliance, inability to complete, or unwillingness to cooperate with regular postoperative follow-up;
20. Other circumstances that the physician considers unsuitable for this clinical trial.
21. Anti-Aβ monoclonal antibody treatment has been received within half a year